北美品牌仿制药市场规模、趋势、增长报告2032

Q: 《北美品牌仿製藥市場》报告涵盖的主要细分市场是什么？

市场是基于 北美品牌仿製藥市場細分，按藥物類別（抗高血壓藥、荷爾蒙藥物、抗代謝藥、降血脂藥、抗癲癇藥、烷化劑、抗憂鬱藥、抗精神病藥及其他）、應用領域（心血管疾病、疼痛管理和抗發炎、腫瘤、糖尿病、神經系統疾病、胃腸道疾病、皮膚病及其他）、給藥途徑（口服、注射、外用及其他）、產品類型（加值品牌仿製藥、商品名仿製藥）、患者人群（成人、老年人、兒童）、最終用戶（醫院、診所、家庭護理機構、學術和研究機構及其他）、分銷渠道（零售藥店、醫院藥房、直接招標及其他）——行業趨勢及至2032年的預測 进行细分的。

North America Branded Generics Market

市场规模（十亿美元）

CAGR : 7.00 %

USD 55.89 Billion USD 95.79 Billion 2024 2032

Forecast Period	2025 –2032
Market Size (Base Year)	USD 55.89 Billion
Market Size (Forecast Year)	USD 95.79 Billion
CAGR	7.00 %
Major Markets Players	Teva Pharmaceutical Industries Ltd. Viatris Inc. Sandoz Group AG Dr. Reddy’s Laboratories Ltd. Sun Pharmaceutical Industries Ltd.

北美品牌仿製藥市場細分，按藥物類別（抗高血壓藥、荷爾蒙藥物、抗代謝藥、降血脂藥、抗癲癇藥、烷化劑、抗憂鬱藥、抗精神病藥及其他）、應用領域（心血管疾病、疼痛管理和抗發炎、腫瘤、糖尿病、神經系統疾病、胃腸道疾病、皮膚病及其他）、給藥途徑（口服、注射、外用及其他）、產品類型（加值品牌仿製藥、商品名仿製藥）、患者人群（成人、老年人、兒童）、最終用戶（醫院、診所、家庭護理機構、學術和研究機構及其他）、分銷渠道（零售藥店、醫院藥房、直接招標及其他）——行業趨勢及至2032年的預測

北美品牌仿製藥市場規模

2024年北美品牌仿製藥市場價值為558.9億美元，預計到2032年將達到957.9億美元。
在2025年至2032年的預測期內，該市場預計將以7.0%的複合年增長率成長，主要驅動因素包括醫療保健支出增加、慢性病盛行率上升以及已開發市場和新興市場對價格合理、高品質藥物的需求。
這一增長也受到原研藥專利到期、政府支持經濟有效療法的政策、新興經濟體醫療保健覆蓋範圍擴大以及數位醫療和電子藥房管道日益普及的推動。此外，領先製藥公司在藥物製劑方面的持續創新、改進的患者依從性策略以及不斷擴大的品牌仿製藥產品組合，預計也將加速全球市場的擴張。

北美品牌仿製藥市場分析

北美品牌仿製藥市場正經歷強勁成長，這主要得益於消費者對兼具仿製藥價格優勢和品牌知名度的高品質、高性價比藥品的需求不斷增長。品牌仿製藥在提高患者用藥依從性、擴大基本藥物的可及性以及為新興市場和已開發市場的製藥公司創造收入機會方面發揮著至關重要的作用。該市場面臨的挑戰包括各國監管差異、價格壓力以及為維持品牌忠誠度而需要持續創新。
慢性病管理、腫瘤、心血管和傳染病治療領域是關鍵的成長驅動力。非傳染性疾病盛行率的上升、公眾健康意識的增強以及新興經濟體醫療服務覆蓋範圍的擴大，都推動了對品牌仿製藥的需求。此外，生物相似藥和專科仿製藥的日益普及也正在重塑市場格局，它們在保持療效和安全性的同時，為昂貴的原廠藥提供了替代方案。製藥公司正利用行銷策略、病患教育和策略合作夥伴關係來提高品牌仿製藥的普及率。
美國憑藉其成熟的仿製藥生產能力、有利的政府政策以及不斷增長的醫療保健支出，在市場中佔據主導地位。北美緊隨其後，這主要得益於對慢性病治療藥物的高需求、不斷擴大的醫療保險覆蓋範圍以及強大的分銷網絡。歐洲市場呈現穩定成長，這得益於仿製藥替代政策、成本控制措施以及對醫療效率日益重視。拉丁美洲、中東和非洲等新興市場正逐步接受仿製藥，這主要歸功於醫療基礎設施的改善、監管的日益協調以及藥品生產能力的提升。
抗高血壓藥物預計將佔據市場主導地位，市場份額為 20.95%，這主要得益於患者對方便用藥、成本效益和廣泛適用性等因素的偏好。

報告範圍及北美品牌仿製藥市場細分

屬性	北美品牌仿製藥市場關鍵洞察
涵蓋部分	依藥物類別：抗高血壓藥、荷爾蒙藥物、抗代謝藥、降血脂藥、抗癲癇藥、烷化劑、抗憂鬱藥、抗精神病藥、其他依應用領域：心血管疾病、疼痛管理與抗發炎、腫瘤學、糖尿病、神經病學、胃腸道疾病、皮膚病學、其他依給藥途徑：口服、注射、外用、其他依產品類型劃分：加值品牌學名藥、商品名學名藥依患者人口統計特徵劃分：成人、老年人、兒童依最終使用者分類：醫院、診所、家庭護理機構、學術及研究機構、其他按分銷管道：零售藥局、醫院藥局、直接招標、其他
覆蓋國家/地區	北美洲我們加拿大墨西哥
主要市場參與者	梯瓦製藥工業股份有限公司（以色列） Viatris 公司（美國）山德士集團（瑞士）瑞迪博士實驗室有限公司（印度）太陽製藥工業有限公司（印度）奧羅賓多製藥（印度）西普拉製藥（印度）費森尤斯卡比（德國）雅培（美國） Glenmark 製藥公司（印度） Hikma Pharmaceuticals PLC（英國）魯賓製藥（印度） Emcure製藥（印度）博士倫健康公司（加拿大） Mankind Pharma（印度） Jubilant Pharma（印度） Natco Pharma（印度） ARISTO製藥有限公司（印度） Biocon有限公司（印度） Torrent Pharmaceuticals Ltd.（印度） Endo公司（美國） Alembic製藥有限公司（印度） SAGENT製藥（美國） Panacea Biotec（印度）
市場機遇	新興市場品牌仿製藥的擴張主要藥物專利懸崖拓展至專科及複雜仿製藥領域
加值資料資訊集	除了對市場狀況（如市場價值、成長率、細分、地理覆蓋範圍和主要參與者）的洞察之外，Data Bridge Market Research 精心編制的市場報告還包括深入的專家分析、患者流行病學、產品線分析、定價分析和監管框架。

北美品牌仿製藥市場趨勢

“消費者對價格合理、品質優良的藥品需求不斷增長，推動北美品牌仿製藥市場成長”

醫療保健成本不斷上漲、人口老化以及慢性病和生活方式相關疾病的日益普遍，推動了北美對價格合理且品質優良的藥品的需求，從而促進了品牌仿製藥的成長。品牌仿製藥在保持高療效和安全性的同時，為原廠藥提供了一種經濟有效的替代方案，使其在已開發市場和新興市場都至關重要。
各國政府和醫療支付方正積極透過政策、報銷框架和仿製藥替代計劃來推廣品牌仿製藥的使用，以控制醫療支出、擴大治療覆蓋範圍並提高患者依從性。這些措施正在促進多個治療領域（包括心血管疾病、糖尿病、腫瘤和中樞神經系統疾病）的市場接受度。
例如，2024年3月，美國FDA批准了多種針對糖尿病和高血壓等高需求治療領域的新型品牌仿製藥，顯示市場研發管線日益活躍，監管機構也大力支持提供更具成本效益的品牌藥替代品。這說明北美品牌仿製藥市場正在持續擴張，以滿足患者和醫療保健系統的需求。
新興經濟體，尤其是美國和拉丁美洲，由於醫療基礎設施的擴張、中產階級人口的壯大以及政府旨在提高治療可及性的舉措，品牌仿製藥的普及速度正在加快。各公司正在擴大本地生產規模、增加研發投入並改善分銷網絡，以滿足這些地區日益增長的需求。
隨著北美醫療保健系統不斷強調可負擔性、可近性和治療依從性，品牌仿製藥在確保可持續醫療保健服務方面的作用將變得越來越重要，同時推動製造、包裝和以患者為中心的藥物開發方面的創新。

北美品牌仿製藥市場動態

司機

“重磅藥物專利到期”

重磅藥物專利即將到期是推動北美品牌仿製藥市場擴張的最強勁的結構性因素之一。當高收入的創新藥失去專利保護時，仿製藥和生物相似藥生產商便可推出競爭版本，從而削弱創新藥的市場份額，並將需求轉向價格更低的替代藥物。
這場「專利懸崖」引發了一系列下游效應：製造商爭相提交簡略新藥申請（ANDA）或生物類似藥申請，監管機構加快審查，支付方越來越傾向於仿製藥，患者可以獲得更便宜的品牌仿製藥。
過去十年間，大型治療藥物專利保護期的大量喪失，為仿製藥現有廠商和新進業者創造了反覆出現的機遇窗口，重塑了價格格局，促進了仿製藥生產的整合，並加速了其向新興市場的地域擴張。事實上，專利到期帶來的巨大收益往往為投資研發複雜的仿製藥和生物相似藥提供了經濟上的合理性。
重要的是，專利懸崖的時機和可預測性為仿製藥公司提供了戰略規劃窗口，使其能夠提前預估產品上市時間、投資研發管線、建立聯盟，並在專利獨佔權喪失前預先提交監管文件。
因此，品牌仿製藥領域成為一個週期性競爭的前沿陣地，與重磅藥物專利到期密切相關。

克制/挑戰

“專利訴訟與智慧財產權風險”

專利訴訟和智慧財產權風險對北美品牌仿製藥市場構成重大限制。專利糾紛的複雜性和持續時間可能會延遲仿製藥的上市，阻礙市場競爭，並導致藥品價格居高不下。
這些法律糾紛通常涉及多層專利權主張，包括用途專利和次要專利，這可以延長品牌藥的獨佔期，使其超過其原始專利到期日。
此外，應對專利侵權訴訟的經濟負擔可能會阻礙仿製藥生產商，尤其是規模較小的公司進入市場。專利法的不斷演變以及原廠藥公司對專利組合的策略性運用，進一步加劇了市場動態的複雜性，並可能導致全球範圍內出現品牌藥與仿製藥並存的市場格局。
例如，2025年10月，《經濟時報》報道稱，總部位於海得拉巴的Natco Pharma公司贏得了與瑞士製藥公司羅氏就治療脊髓性肌肉萎縮症藥物Risdiplam的專利糾紛。
這些法律和財務障礙既影響製造商的獲利能力，也影響病患取得價格合理的藥品。總體而言，專利訴訟和智慧財產權風險仍然是影響北美品牌仿製藥市場競爭和成長的關鍵限制因素。

北美品牌仿製藥市場範圍

北美品牌仿製藥市場分為七個主要部分，這些部分是根據藥物類別、應用、給藥途徑、產品類型、患者人口統計特徵、最終用戶和分銷管道劃分的。

• 依藥物類別

根據藥物類別，北美品牌仿製藥市場可細分為抗高血壓藥、荷爾蒙藥物、抗代謝藥、降血脂藥、抗癲癇藥、烷化劑、抗憂鬱藥、抗精神病藥及其他藥物。預計到2025年，抗高血壓藥物將佔據市場主導地位，市場份額達20.95%，這主要得益於全球心血管疾病患病率的上升、人們對高血壓管理意識的增強，以及患者和醫療服務提供者對經濟實惠的仿製藥替代品的日益青睞。

預計在 2025 年至 2032 年的預測期內，抗高血壓藥物市場將以 9.8% 的複合年增長率增長，這主要得益於固定劑量組合療法的不斷創新、政府推廣平價藥物的舉措以及新興經濟體醫療保健覆蓋範圍的擴大，這些因素共同促進了抗高血壓品牌仿製藥的普及。

• 透過申請

根據應用領域，市場可細分為心血管疾病、疼痛管理和抗發炎、腫瘤、糖尿病、神經系統疾病、胃腸道疾病、皮膚病及其他領域。預計到2025年，心血管疾病領域將佔據市場主導地位，市場份額達27.88%，這主要得益於全球心臟相關疾病患病率的上升、老年人口的增長、人們對心血管疾病預防保健意識的提高以及經濟實惠的品牌仿製藥的普及。

預計心血管疾病領域將以 8.6% 的複合年增長率穩步增長，因為新興市場的醫療保健系統提高了基本藥物的可及性，固定劑量組合療法越來越受歡迎，而且持續的研究和開發提高了品牌仿製藥在心血管治療中的療效和安全性。

• 依管理途徑

根據給藥途徑，北美品牌仿製藥市場可分為口服、注射、外用和其他給藥途徑。預計到2025年，口服給藥途徑將佔據市場主導地位，市場份額達54.98%，這主要歸功於口服給藥的便利性、患者依從性高、口服製劑的廣泛可及性以及與其他給藥途徑相比的成本效益。

預計在預測期內，口服藥物市場將加速成長 7.2%，這得益於需要長期用藥的慢性疾病盛行率不斷上升、人們對自我給藥療法的偏好日益增強，以及具有更高生物利用度和更人性化設計的創新口服製劑的不斷推出。

• 依產品類型

根據產品類型，市場可分為高附加價值品牌仿製藥和商品名仿製藥。預計到2025年，高附加價值品牌仿製藥將佔據市場主導地位，市場份額達66.21%，這主要得益於其更高的療效、更佳的安全性、以患者為中心的配方以及與標準仿製藥相比更具差異化的治療優勢。

由於醫療保健提供者越來越傾向於選擇能夠提高患者依從性的製劑、對聯合療法的需求不斷增長、藥物輸送技術的持續創新以及對解決慢性病和復雜疾病治療中未滿足的醫療需求的關注，增值品牌仿製藥領域的重要性日益凸顯，並以 7.1% 的複合年增長率增長。

• 依患者人口統計特徵

根據患者人口統計數據，市場分為成人、老年和兒童三個部分。預計到2025年，成人市場將佔據主導地位，市場份額達64.43%，這主要是由於成人人群中慢性病和生活方式相關疾病（如心血管疾病、糖尿病和高血壓）的患病率較高，從而推動了對品牌仿製藥的持續需求。

預計成人市場將以 7.1% 的複合年增長率增長，這主要得益於醫療保健意識的提高、獲得價格合理的藥物的機會增加、新興經濟體中產階級人口的增長，以及成人患者對具有更好療效和依從性的增值品牌仿製藥的偏好。

• 由最終用戶

根據最終用戶劃分，市場可分為醫院、診所、家庭護理機構、學術及研究機構和其他機構。預計到2025年，醫院將佔據市場主導地位，市場份額達50.54%，這主要得益於醫院龐大的患者治療量、對品牌藥和高品質仿製藥在重症監護方面的偏好，以及醫院集中採購模式確保了基本藥物的穩定供應。

預計在 2025 年至 2032 年期間，醫院業將錄得最快的增長速度，達到 7.4%，這主要得益於醫院基礎設施的擴張、專科醫院和綜合醫院數量的增加、慢性病和急性病住院人數的上升，以及為了改善治療效果，住院治療中越來越多地採用增值仿製藥。

• 透過分銷管道

根據分銷管道，市場可分為零售藥局、醫院藥房、直接招標和其他管道。預計到2025年，零售藥局通路將佔據市場主導地位，市佔率達51.56%，主要得益於品牌仿製藥透過零售網點的廣泛供應、消費者對便捷購藥的需求，以及連鎖藥局和獨立藥局在城市和半城市地區的強大影響力。

預計在 2025 年至 2032 年期間，零售藥局行業將以 7.2% 的最快增速增長，這主要得益於自我用藥趨勢的增加、人們對經濟實惠的品牌仿製藥的認識不斷提高、藥店網絡的擴張以及政府通過零售渠道支持以可負擔的價格獲得基本藥物的舉措。

北美品牌仿製藥市場－區域分析

預計到 2025 年，美國將以 70.77% 的最大收入份額主導北美品牌仿製藥市場，這主要得益於對價格實惠且質量優良的藥品的強勁需求以及該地區醫療保健支出的不斷增長。
政府加強對醫療保健基礎設施的支持力度、慢性病患病率不斷上升以及人們對治療依從性的認識不斷提高，這些因素共同推動了品牌仿製藥的普及。
印度、美國、日本和韓國等國家憑藉其完善的藥品生產能力、對仿製藥的監管支持以及對國內醫療保健生產不斷增長的投資，在該地區處於領先地位。
此外，有利於本地藥品生產、醫療保健和藥品出口的政策進一步加速了美國市場的成長。

北美品牌仿製藥市場洞察

預計到2025年，北美將佔據北美品牌仿製藥市場約21.42%的份額，這主要得益於其先進的醫療基礎設施、健全的監管框架以及眾多領先製藥公司的存在。該地區的成長動力主要來自對慢性病治療藥物需求的不斷增長、專科仿製藥的高普及率以及生物類似藥研發的強勁勢頭。美國和加拿大持續增加對國內藥品生產、數位化醫療和以病人為中心的醫療服務計畫的投入，這些措施正在推動品牌仿製藥的普及。此外，對成本效益高的療法和醫療效率的日益重視也提升了該地區的市場滲透率。

美國北美品牌仿製藥市場洞察

美國預計將主導北美市場，這主要得益於其強大的醫藥生態系統、高額的醫療保健支出以及對專科藥和高價值仿製藥的快速接受。慢性病、腫瘤治療和心血管疾病的日益普遍持續推動對品牌仿製藥的需求。美國在醫療基礎設施、數位療法和製造業回流方面的投資進一步加速了市場成長。憑藉完善的分銷網絡、先進的監管支援和強大的研發能力，美國仍然是全球規模最大、利潤最豐厚的品牌仿製藥市場之一。

加拿大北美品牌仿製藥市場洞察

加拿大憑藉其強大的醫療保健基礎設施、先進的藥品生產能力以及政府鼓勵國內藥品生產的舉措，在北美品牌仿製藥市場佔據重要地位。該國對慢性病管理、腫瘤和心血管治療的重視，正在推動對品牌仿製藥的需求成長。此外，製藥公司與研究機構之間的策略合作，正在推動高價值仿製藥和專科療法的創新。法國日益重視醫療保健的可近性、可負擔性和治療依從性，進一步鞏固了其在歐洲醫藥領域的重要地位。

市場上的主要市場領導者包括：

梯瓦製藥工業股份有限公司（以色列）
Viatris 公司（美國）
山德士集團（瑞士）
瑞迪博士實驗室有限公司（印度）
太陽製藥工業有限公司（印度）
奧羅賓多製藥（印度）
西普拉製藥（印度）
費森尤斯卡比（德國）
雅培（美國）
Glenmark 製藥公司（印度）
Hikma Pharmaceuticals PLC（英國）
魯賓製藥（印度）
Emcure製藥（印度）
博士倫健康公司（加拿大）
Mankind Pharma（印度）
Jubilant Pharma（印度）
Natco Pharma（印度）
ARISTO製藥有限公司（印度）
Biocon有限公司（印度）
Torrent Pharmaceuticals Ltd.（印度）
Endo公司（美國）
Alembic製藥有限公司（印度）
SAGENT製藥（美國）
Panacea Biotec（印度）

北美品牌仿製藥市場最新動態

2025年10月，美國FDA批准了UZEDY（利培酮）緩釋注射混懸液的適應症擴展。除成人外，該藥現獲準用於治療13至17歲兒童及青少年的精神分裂症。這為患有這種慢性疾病的年輕患者提供了長效治療選擇。
2025年8月，梯瓦製藥（Teva）獲得美國FDA批准，推出了第一台Saxenda（利拉魯肽）注射仿製藥。這種仿製GLP-1受體激動劑核准用於成人和兒童患者的體重管理，為慢性體重管理提供了更方便的選擇。
2025年8月，Viatris公司首個用於治療缺鐵性貧血的藥物－蔗糖鐵注射劑仿製藥獲得美國FDA核准。這項進展為美國患者和醫療機構提供了更經濟實惠的治療選擇。此次獲準進一步豐富了Viatris公司的仿製注射劑產品組合，並提高了患者獲得此關鍵療法的途徑。
2025年4月，Viatris公司向日本厚生勞動省提交了補充新藥申請，尋求批准其藥物EFFEXOR（文拉法辛）用於治療廣泛性焦慮症。此舉旨在擴大該藥物在日本市場的治療用途。如果獲得批准，將為日本的廣泛性焦慮症患者提供新的治療選擇。

SKU-75019

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 BRAND COMPARATIVE ANALYSIS OF THE NORTH AMERICA BRANDED GENERICS MARKET

TABLE 2 PATENT LANDSCAPE

TABLE 3 NORTH AMERICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 4 NORTH AMERICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 NORTH AMERICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 NORTH AMERICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 NORTH AMERICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 NORTH AMERICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 NORTH AMERICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 10 NORTH AMERICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 NORTH AMERICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 NORTH AMERICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 13 NORTH AMERICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 NORTH AMERICA HORMONES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 15 NORTH AMERICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 16 NORTH AMERICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 17 NORTH AMERICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 NORTH AMERICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 19 NORTH AMERICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 20 NORTH AMERICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 NORTH AMERICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 22 NORTH AMERICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 23 NORTH AMERICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 24 NORTH AMERICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 NORTH AMERICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 26 NORTH AMERICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 27 NORTH AMERICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 28 NORTH AMERICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 NORTH AMERICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 NORTH AMERICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 NORTH AMERICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 32 NORTH AMERICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 33 NORTH AMERICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 NORTH AMERICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 NORTH AMERICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 NORTH AMERICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 NORTH AMERICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 NORTH AMERICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 NORTH AMERICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 NORTH AMERICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 NORTH AMERICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 NORTH AMERICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 43 NORTH AMERICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 44 NORTH AMERICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 NORTH AMERICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 46 NORTH AMERICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 47 NORTH AMERICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 48 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 49 NORTH AMERICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 50 NORTH AMERICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 NORTH AMERICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 52 NORTH AMERICA ANTI-PSYCHOTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 NORTH AMERICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 NORTH AMERICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 NORTH AMERICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 NORTH AMERICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 57 NORTH AMERICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 58 NORTH AMERICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 59 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 60 NORTH AMERICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 61 NORTH AMERICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 62 NORTH AMERICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 NORTH AMERICA PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 NORTH AMERICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 NORTH AMERICA ONCOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 NORTH AMERICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 NORTH AMERICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 NORTH AMERICA DIABETES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 NORTH AMERICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 71 NORTH AMERICA NEUROLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 NORTH AMERICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 NORTH AMERICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 74 NORTH AMERICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 75 NORTH AMERICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 76 NORTH AMERICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 78 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 NORTH AMERICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 80 NORTH AMERICA ORAL IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 81 NORTH AMERICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 NORTH AMERICA INJECTABLE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 83 NORTH AMERICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 84 NORTH AMERICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 85 NORTH AMERICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 87 NORTH AMERICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 88 NORTH AMERICA VALUE-ADDED BRANDED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 89 NORTH AMERICA TRADE NAMED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 90 NORTH AMERICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 91 NORTH AMERICA ADULT IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 92 NORTH AMERICA GERIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 93 NORTH AMERICA PEDIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 94 NORTH AMERICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 95 NORTH AMERICA HOSPITALS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 96 NORTH AMERICA CLINICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 97 NORTH AMERICA HOMECARE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 98 NORTH AMERICA ACADEMIC & RESEARCH INSTITUTES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 99 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 100 NORTH AMERICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 101 NORTH AMERICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 102 NORTH AMERICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 NORTH AMERICA HOSPITAL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 104 NORTH AMERICA DIRECT TENDERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 105 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 106 NORTH AMERICA BRANDED GENERICS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 107 NORTH AMERICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 108 NORTH AMERICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 NORTH AMERICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 NORTH AMERICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 NORTH AMERICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 NORTH AMERICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 NORTH AMERICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 NORTH AMERICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 NORTH AMERICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 NORTH AMERICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 NORTH AMERICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 NORTH AMERICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 NORTH AMERICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 NORTH AMERICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 NORTH AMERICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 NORTH AMERICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 NORTH AMERICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 NORTH AMERICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 NORTH AMERICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 NORTH AMERICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 NORTH AMERICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 NORTH AMERICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 NORTH AMERICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 NORTH AMERICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 131 NORTH AMERICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 NORTH AMERICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 133 NORTH AMERICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 NORTH AMERICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 NORTH AMERICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 NORTH AMERICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 NORTH AMERICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 NORTH AMERICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 NORTH AMERICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 NORTH AMERICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 NORTH AMERICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 NORTH AMERICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 NORTH AMERICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 144 NORTH AMERICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 145 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 NORTH AMERICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 NORTH AMERICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 NORTH AMERICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 149 NORTH AMERICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 NORTH AMERICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 NORTH AMERICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 NORTH AMERICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 NORTH AMERICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 NORTH AMERICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 NORTH AMERICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 156 NORTH AMERICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 NORTH AMERICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 NORTH AMERICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 NORTH AMERICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 NORTH AMERICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 NORTH AMERICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 NORTH AMERICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 NORTH AMERICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 NORTH AMERICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 167 NORTH AMERICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 NORTH AMERICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 NORTH AMERICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 NORTH AMERICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 171 NORTH AMERICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 172 NORTH AMERICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 173 NORTH AMERICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 NORTH AMERICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 U.S. BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 176 U.S. ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 U.S. DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 U.S. ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 U.S. ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 180 U.S. BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 U.S. CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 U.S. DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 U.S. ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 U.S. CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 U.S. HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 U.S. STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 U.S. SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 U.S. ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 U.S. PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 U.S. ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 U.S. THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 U.S. OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 U.S. ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 U.S. PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 U.S. PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 U.S. FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 U.S. LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 U.S. STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 199 U.S. COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 U.S. FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 U.S. BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 U.S. PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 U.S. ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 U.S. ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 U.S. NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 U.S. NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 U.S. ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 U.S. TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 U.S. ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 U.S. ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 U.S. SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 U.S. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 213 U.S. TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 214 U.S. ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 U.S. MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 U.S. NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 U.S. ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 U.S. SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 U.S. FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 U.S. PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 U.S. THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 U.S. NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 U.S. BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 224 U.S. CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 U.S. PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 U.S. ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 U.S. SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 U.S. HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 U.S. DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 U.S. NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 231 U.S. GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 U.S. DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 U.S. OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 U.S. BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 235 U.S. ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 236 U.S. INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 U.S. TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 238 U.S. BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 239 U.S. BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 240 U.S. BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 241 U.S. BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 242 U.S. RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 CANADA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 244 CANADA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 245 CANADA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 CANADA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 CANADA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 CANADA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 249 CANADA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 CANADA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 CANADA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 CANADA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 CANADA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 CANADA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 CANADA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 CANADA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 CANADA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 CANADA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 CANADA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 262

TABLE 261 CANADA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 CANADA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 CANADA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 264 CANADA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 CANADA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 CANADA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 CANADA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 CANADA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 CANADA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 CANADA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 CANADA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 CANADA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 CANADA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 CANADA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 CANADA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 CANADA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 CANADA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 278 CANADA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 CANADA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 CANADA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 CANADA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 CANADA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 CANADA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 CANADA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 CANADA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 286 CANADA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 CANADA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 288 CANADA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 289 CANADA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 CANADA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 291 CANADA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 292 CANADA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 293 CANADA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 CANADA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 CANADA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 CANADA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 297 CANADA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 CANADA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 CANADA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 CANADA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 CANADA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 CANADA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 303 CANADA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 304 CANADA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 CANADA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 CANADA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 CANADA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 CANADA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 309 CANADA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 310 CANADA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 311 CANADA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 MEXICO BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 313 MEXICO ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 MEXICO DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 MEXICO ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 MEXICO ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 MEXICO BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 318 MEXICO CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 MEXICO DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 MEXICO ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 MEXICO CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 MEXICO HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 MEXICO STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 MEXICO SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 MEXICO ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 MEXICO PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 MEXICO ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 MEXICO THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 MEXICO OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 MEXICO ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 MEXICO PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 MEXICO PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 MEXICO FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 MEXICO LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 MEXICO STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 336 MEXICO COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 MEXICO FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 338 MEXICO BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 MEXICO PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 MEXICO ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 341 MEXICO ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 342 MEXICO NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 MEXICO NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 344 MEXICO ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 MEXICO TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 MEXICO ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 MEXICO ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 MEXICO SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 349 MEXICO SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 MEXICO TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 MEXICO ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 MEXICO MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 MEXICO NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 MEXICO ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 MEXICO SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 MEXICO FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 MEXICO PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 MEXICO THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 MEXICO NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 MEXICO BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 361 MEXICO CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 MEXICO PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 363 MEXICO ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 MEXICO SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 MEXICO HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 MEXICO DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 MEXICO NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 MEXICO GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 MEXICO DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 MEXICO OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 371 MEXICO BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 372 MEXICO ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 MEXICO INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 MEXICO TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 MEXICO BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 MEXICO BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 377 MEXICO BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 378 MEXICO BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 379 MEXICO RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

图片列表

FIGURE 1 NORTH AMERICA BRANDED GENERICS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA BRANDED GENERICS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA BRANDED GENERICS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA BRANDED GENERICS MARKET: NORTH AMERICA VS. REGIONAL ANALYSIS

FIGURE 5 NORTH AMERICA BRANDED GENERICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA BRANDED GENERICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA BRANDED GENERICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA BRANDED GENERICS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EXECUTIVE SUMMARY

FIGURE 10 STRATEGIC DECISIONS

FIGURE 11 NINE SEGMENTS COMPRISE THE NORTH AMERICA BRANDED GENERICS MARKET, BY DRUG CLASS (2024)

FIGURE 12 NORTH AMERICA BRANDED GENERICS MARKET: SEGMENTATION

FIGURE 13 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS ARE EXPECTED TO DRIVE THE NORTH AMERICA BRANDED GENERICS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 14 ANTI-HYPERTENSIVE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA BRANDED GENERICS MARKET IN 2025 & 2032

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE NORTH AMERICA BRANDED GENERICS MARKET

FIGURE 16 NORTH AMERICA BRANDED GENERIC MARKET: BY DRUG CLASS, 2024

FIGURE 17 NORTH AMERICA BRANDED GENERIC MARKET: BY DRUG CLASS, 2025 TO 2032 (USD THOUSAND)

FIGURE 18 NORTH AMERICA BRANDED GENERIC MARKET: BY DRUG CLASS, CAGR (2025- 2032)

FIGURE 19 NORTH AMERICA BRANDED GENERIC MARKET: BY DRUG CLASS, LIFELINE CURVE

FIGURE 20 NORTH AMERICA BRANDED GENERICS MARKET: BY APPLICATION, 2024

FIGURE 21 NORTH AMERICA BRANDED GENERICS MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)

FIGURE 22 NORTH AMERICA BRANDED GENERICS MARKET: BY APPLICATION, CAGR (2025- 2032)

FIGURE 23 NORTH AMERICA BRANDED GENERICS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 24 NORTH AMERICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2024

FIGURE 25 NORTH AMERICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)

FIGURE 26 NORTH AMERICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)

FIGURE 27 NORTH AMERICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 28 NORTH AMERICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2024

FIGURE 29 NORTH AMERICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)

FIGURE 30 NORTH AMERICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, CAGR (2025- 2032)

FIGURE 31 NORTH AMERICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 32 NORTH AMERICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2024

FIGURE 33 NORTH AMERICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2025 TO 2032 (USD THOUSAND)

FIGURE 34 NORTH AMERICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2025- 2032)

FIGURE 35 NORTH AMERICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE

FIGURE 36 NORTH AMERICA BRANDED GENERICS MARKET: BY END USER, 2024

FIGURE 37 NORTH AMERICA BRANDED GENERICS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)

FIGURE 38 NORTH AMERICA BRANDED GENERICS MARKET: BY END USER, CAGR (2025- 2032)

FIGURE 39 NORTH AMERICA BRANDED GENERICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 NORTH AMERICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 41 NORTH AMERICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)

FIGURE 42 NORTH AMERICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)

FIGURE 43 NORTH AMERICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 NORTH AMERICA BRANDED GENERICS MARKET: SNAPSHOT (2024)

FIGURE 45 NORTH AMERICA BRANDED GENERICS MARKET: COMPANY SHARE 2024 (%)

查看详细信息

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

《北美品牌仿製藥市場》报告涵盖的主要细分市场是什么？

市场是基于北美品牌仿製藥市場細分，按藥物類別（抗高血壓藥、荷爾蒙藥物、抗代謝藥、降血脂藥、抗癲癇藥、烷化劑、抗憂鬱藥、抗精神病藥及其他）、應用領域（心血管疾病、疼痛管理和抗發炎、腫瘤、糖尿病、神經系統疾病、胃腸道疾病、皮膚病及其他）、給藥途徑（口服、注射、外用及其他）、產品類型（加值品牌仿製藥、商品名仿製藥）、患者人群（成人、老年人、兒童）、最終用戶（醫院、診所、家庭護理機構、學術和研究機構及其他）、分銷渠道（零售藥店、醫院藥房、直接招標及其他）——行業趨勢及至2032年的預測进行细分的。

当前北美品牌仿製藥市場的市场规模是多少？

在2024年，北美品牌仿製藥市場的规模估计为55.89 USD Billion美元。

预计北美品牌仿製藥市場的增长率是多少？

北美品牌仿製藥市場预计将在2025年至2032年的预测期内以CAGR 7%的速度增长。

谁是北美品牌仿製藥市場的主要参与者？

市场上的主要参与者包括Teva Pharmaceutical Industries Ltd. ,Viatris Inc. ,Sandoz Group AG ,Dr. Reddy’s Laboratories Ltd. ,Sun Pharmaceutical Industries Ltd.。

北美品牌仿製藥市場規模、份額及趨勢分析報告－產業概況及至2032年預測

通过敏捷供应链咨询解决关税挑战

North America Branded Generics Market

CAGR : 7.00 %

北美品牌仿製藥市場規模

北美品牌仿製藥市場分析

報告範圍及北美品牌仿製藥市場細分

北美品牌仿製藥市場關鍵洞察

北美品牌仿製藥市場趨勢

北美品牌仿製藥市場動態

北美品牌仿製藥市場範圍

北美品牌仿製藥市場－區域分析

北美品牌仿製藥市場最新動態

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

ISO認證

报告

市场洞察

支持

解决方案

北美品牌仿製藥市場規模、份額及趨勢分析報告－產業概況及至2032年預測

通过敏捷供应链咨询解决关税挑战

North America Branded Generics Market

CAGR : 7.00 %

北美品牌仿製藥市場規模

北美品牌仿製藥市場分析

報告範圍及北美品牌仿製藥市場細分

北美品牌仿製藥市場關鍵洞察

北美品牌仿製藥市場趨勢

北美品牌仿製藥市場動態

北美品牌仿製藥市場範圍

北美品牌仿製藥市場－區域分析

北美品牌仿製藥市場最新動態

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面